AstraZeneca’s Danicopan yields promising results in ALPHA Phase 3 trial in PNH
In a significant development in the healthcare industry, AstraZeneca has released positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III trial. The study focused on Danicopan as an add-on to standard of care C5 inhibitor therapy Ultomiris (ravulizumab) or Soliris (eculizumab). This advancement is particularly crucial for patients […]
